How should I interpret a liver biopsy showing high‑grade small‑cell carcinoma with immunohistochemistry positive for CD56 and focal cytokeratin (AE1/AE3), negative for TTF‑1, Napsin A, p40, synaptophysin, and chromogranin, and a Ki‑67 proliferation index >90%, and what are the recommended next diagnostic and treatment steps?

Interpretation and Management of Hepatic Small Cell Carcinoma

This liver biopsy demonstrates metastatic small cell carcinoma to the liver with an atypical immunophenotype that is TTF-1 negative, requiring urgent identification of the primary site and initiation of platinum-based chemotherapy.

Pathologic Interpretation

The immunohistochemical profile presents an unusual pattern for small cell carcinoma:

• Positive markers: CD56, focal cytokeratin (AE1/AE3), and extremely high Ki-67 >90% 1
• Negative markers: TTF-1, Napsin A, p40, synaptophysin, and chromogranin 1

Key Diagnostic Considerations

This is consistent with small cell carcinoma, despite the atypical immunoprofile. The diagnosis is supported by:

• CD56 positivity: CD56 is expressed in 92-98% of small cell carcinomas and is highly sensitive for this diagnosis 2, 3
• Ki-67 >90%: The extremely high proliferation index (typically 50-100% in SCLC) strongly supports small cell carcinoma over carcinoid tumors 1, 3
• Focal cytokeratin positivity: Nearly all small cell carcinomas are positive for broad-spectrum cytokeratins like AE1/AE3 1

Critical Caveat: TTF-1 Negativity

Approximately 9-15% of small cell carcinomas are TTF-1 negative, so this does not exclude the diagnosis 1, 4. The absence of TTF-1 along with negative synaptophysin and chromogranin (classic neuroendocrine markers) represents the minority subset where fewer than 10% of SCLCs are negative for all traditional neuroendocrine markers 1.

Primary Site Determination

The TTF-1 negativity raises two critical possibilities:

1. Extrapulmonary small cell carcinoma (liver, gastrointestinal tract, genitourinary tract) 5, 6
2. TTF-1-negative pulmonary small cell carcinoma (10-15% of lung primaries) 1, 4

The negative p40 effectively excludes squamous differentiation 7. The focal rather than diffuse cytokeratin staining and absence of classic neuroendocrine markers makes this a diagnostically challenging case 1.

Immediate Diagnostic Work-Up

Comprehensive staging must be completed urgently to identify the primary site and determine limited versus extensive stage disease:

Required Imaging Studies

• Contrast-enhanced CT chest/abdomen/pelvis: To identify potential lung primary and assess extent of disease 8
• Brain MRI with contrast (preferred over CT): Essential given >50% risk of brain metastases in SCLC 1, 8
• PET-CT: May help identify occult primary site and assess metabolic activity 9

Additional Diagnostic Considerations

• Upper and lower endoscopy: Consider if imaging does not reveal lung primary, to evaluate for gastrointestinal primary 5, 6
• Genitourinary evaluation: If no other primary identified, particularly in appropriate clinical context 5
• Serum tumor markers: Chromogranin A, neuron-specific enolase (though less specific) 10

Staging Classification

Use both Veterans Affairs (VA) and TNM staging systems:

• Limited-stage: Disease confined to ipsilateral hemithorax that can be safely encompassed in radiation field (stage I-III, T any, N any, M0) 8
• Extensive-stage: Stage IV disease (T any, N any, M1a/b/c) or disease too extensive for safe radiation 8

Given hepatic involvement, this patient has extensive-stage disease by definition 8.

Treatment Recommendations

First-Line Systemic Therapy

Initiate platinum-based chemotherapy immediately (maximum 4-6 cycles): 1

Preferred regimens for extensive-stage disease:

• Carboplatin AUC 5-6 day 1 + etoposide 100 mg/m² days 1-2, every 3 weeks 1
• Cisplatin 75 mg/m² day 1 + etoposide 80 mg/m² days 1-2, every 3 weeks 1

Category 1 recommendation: Cisplatin/etoposide is the standard of care 1.

Prophylactic Cranial Irradiation (PCI)

If patient achieves response to chemotherapy, consider PCI:

• Reduces 3-year brain metastasis incidence from 58.6% to 33.3% 1
• Provides survival benefit in responding patients 1

Radiation Therapy

Thoracic radiation is NOT indicated for extensive-stage disease with hepatic metastases unless for palliation of specific symptomatic sites 1, 8.

Prognostic Considerations

This patient faces extremely poor prognosis:

• Median survival for extensive-stage SCLC is approximately 8-13 months with chemotherapy 8
• The extremely high Ki-67 >90% indicates highly aggressive biology 1, 3
• Hepatic metastases indicate extensive-stage disease with worse outcomes 8

Common Pitfalls to Avoid

1. Do not delay treatment waiting for primary site identification—small cell carcinoma requires urgent systemic therapy regardless of primary site 5, 8
2. Do not pursue surgical resection of liver metastases—this is systemic disease requiring chemotherapy 8
3. Do not dismiss the diagnosis based on TTF-1 negativity alone—CD56 and Ki-67 are sufficient with appropriate morphology 4, 2, 3
4. Do not use myeloid growth factors during concurrent chemotherapy and radiation (if applicable) 1